Pharmacologically inactive bisphosphonates as an alternative strategy for targeting osteoclasts: in vivo assessment of 5-fluorodeoxyuridine-alendronate in a preclinical model of breast cancer bone metastases
Bisphosphonates have effects that are antiresorptive, antitumor, and antiapoptotic to osteoblasts and osteocytes, but an effective means of eliciting these multiple activities in the treatment of bone metastases has not been identified. Antimetabolite-bisphosphonate conjugates have potential for imp...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2017
|
| In: |
Journal of bone and mineral research
Year: 2016, Jahrgang: 32, Heft: 3, Pages: 536-548 |
| ISSN: | 1523-4681 |
| DOI: | 10.1002/jbmr.3012 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1002/jbmr.3012 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/jbmr.3012 
|
| Verfasserangaben: | Christian Schem, Robert J. Tower, Philipp Kneissl, Anna-Christina Rambow, Graeme M. Campbell, Christine Desel, Timo Damm, Thorsten Heilmann, Sabine Fuchs, Maaz Zuhayra, Anna Trauzold, Claus C. Glüer, Sarah Schott, and Sanjay Tiwari |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580279368 | ||
| 003 | DE-627 | ||
| 005 | 20230427065653.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180822r20172016xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jbmr.3012 |2 doi | |
| 035 | |a (DE-627)1580279368 | ||
| 035 | |a (DE-576)510279368 | ||
| 035 | |a (DE-599)BSZ510279368 | ||
| 035 | |a (OCoLC)1341017341 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schem, Christian |d 1974- |e VerfasserIn |0 (DE-588)124076661 |0 (DE-627)085621986 |0 (DE-576)294009183 |4 aut | |
| 245 | 1 | 0 | |a Pharmacologically inactive bisphosphonates as an alternative strategy for targeting osteoclasts |b in vivo assessment of 5-fluorodeoxyuridine-alendronate in a preclinical model of breast cancer bone metastases |c Christian Schem, Robert J. Tower, Philipp Kneissl, Anna-Christina Rambow, Graeme M. Campbell, Christine Desel, Timo Damm, Thorsten Heilmann, Sabine Fuchs, Maaz Zuhayra, Anna Trauzold, Claus C. Glüer, Sarah Schott, and Sanjay Tiwari |
| 264 | 1 | |c 2017 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First published: 07 October 2016 | ||
| 500 | |a Gesehen am 22.08.2018 | ||
| 520 | |a Bisphosphonates have effects that are antiresorptive, antitumor, and antiapoptotic to osteoblasts and osteocytes, but an effective means of eliciting these multiple activities in the treatment of bone metastases has not been identified. Antimetabolite-bisphosphonate conjugates have potential for improved performance as a class of bone-specific antineoplastic drugs. The primary objective of the study was to determine whether an antimetabolite-bisphosphonate conjugate will preserve bone formation concomitant with antiresorptive and antitumor activity. 5-FdU-ale, a highly stable conjugate between the antimetabolite 5-fluoro-2'-deoxyuridine and the bisphosphonate alendronate, was tested for its therapeutic efficacy in a mouse model of MDA-MB231 breast cancer bone metastases. In vitro testing revealed osteoclasts to be highly sensitive to 5-FdU-ale. In contrast, osteoblasts had significantly reduced sensitivity. Tumor cells were resistant in vitro but in vivo tumor burden was nevertheless significantly reduced compared with untreated mice. Sensitivity to 5-FdU-ale was not mediated through inhibition of farnesyl diphosphate synthase activity, but cell cycle arrest was observed. Although serum tartrate-resistant acid phosphatase (TRAP) levels were greatly reduced by both drugs, there was no significant decrease in the serum bone formation marker osteocalcin with 5-FdU-ale treatment. In contrast, there was more than a fivefold decrease in serum osteocalcin levels with alendronate treatment (p < 0.001). This finding is supported by time-lapse micro-computed tomography analyses, which revealed bone formation volume to be on average 1.6-fold higher with 5-FdU-ale treatment compared with alendronate (p < 0.001). We conclude that 5-FdU-ale, which is a poor prenylation inhibitor but maintains potent antiresorptive activity, does not reduce bone formation and has cytostatic antitumor efficacy. These results document that conjugation of an antimetabolite with bisphosphonates offers flexibility in creating potent bone-targeting drugs with cytostatic, bone protection properties that show limited nephrotoxicity. This unique class of drugs may offer distinct advantages in the setting of targeted adjuvant therapy and chemoprevention of bone diseases. © 2016 American Society for Bone and Mineral Research. | ||
| 534 | |c 2016 | ||
| 650 | 4 | |a 5-FDU-ALE | |
| 650 | 4 | |a ANTIRESORPTIVES | |
| 650 | 4 | |a BISPHOSPHONATES | |
| 650 | 4 | |a BONE DISEASES | |
| 700 | 1 | |a Schott, Sarah |d 1981- |e VerfasserIn |0 (DE-588)133730816 |0 (DE-627)552697281 |0 (DE-576)27460678X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of bone and mineral research |d [Oxford] : Oxford University Press, 1986 |g 32(2017), 3, Seite 536-548 |h Online-Ressource |w (DE-627)320473716 |w (DE-600)2008867-X |w (DE-576)098841300 |x 1523-4681 |7 nnas |a Pharmacologically inactive bisphosphonates as an alternative strategy for targeting osteoclasts in vivo assessment of 5-fluorodeoxyuridine-alendronate in a preclinical model of breast cancer bone metastases |
| 773 | 1 | 8 | |g volume:32 |g year:2017 |g number:3 |g pages:536-548 |g extent:13 |a Pharmacologically inactive bisphosphonates as an alternative strategy for targeting osteoclasts in vivo assessment of 5-fluorodeoxyuridine-alendronate in a preclinical model of breast cancer bone metastases |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jbmr.3012 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/jbmr.3012 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180822 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 133730816 |a Schott, Sarah |m 133730816:Schott, Sarah |d 910000 |d 910400 |e 910000PS133730816 |e 910400PS133730816 |k 0/910000/ |k 1/910000/910400/ |p 13 | ||
| 999 | |a KXP-PPN1580279368 |e 3022933401 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Schem, Christian","roleDisplay":"VerfasserIn","role":"aut","family":"Schem","given":"Christian"},{"roleDisplay":"VerfasserIn","display":"Schott, Sarah","role":"aut","family":"Schott","given":"Sarah"}],"title":[{"title_sort":"Pharmacologically inactive bisphosphonates as an alternative strategy for targeting osteoclasts","subtitle":"in vivo assessment of 5-fluorodeoxyuridine-alendronate in a preclinical model of breast cancer bone metastases","title":"Pharmacologically inactive bisphosphonates as an alternative strategy for targeting osteoclasts"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["First published: 07 October 2016","Gesehen am 22.08.2018"],"recId":"1580279368","language":["eng"],"name":{"displayForm":["Christian Schem, Robert J. Tower, Philipp Kneissl, Anna-Christina Rambow, Graeme M. Campbell, Christine Desel, Timo Damm, Thorsten Heilmann, Sabine Fuchs, Maaz Zuhayra, Anna Trauzold, Claus C. Glüer, Sarah Schott, and Sanjay Tiwari"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"2017"}],"id":{"doi":["10.1002/jbmr.3012"],"eki":["1580279368"]},"physDesc":[{"extent":"13 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["ASBMR, The American Society for Bone and Mineral Research"]},"id":{"issn":["1523-4681"],"doi":["10.1002/(ISSN)1523-4681"],"eki":["320473716"],"zdb":["2008867-X"]},"origin":[{"publisherPlace":"[Oxford] ; Washington, DC ; Hoboken, NJ [u.a.]","publisher":"Oxford University Press ; ASBMR ; Wiley","dateIssuedKey":"1986","dateIssuedDisp":"1986-"}],"recId":"320473716","language":["eng"],"note":["Gesehen am 17.01.24"],"disp":"Pharmacologically inactive bisphosphonates as an alternative strategy for targeting osteoclasts in vivo assessment of 5-fluorodeoxyuridine-alendronate in a preclinical model of breast cancer bone metastasesJournal of bone and mineral research","type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"JBMR Online"}],"part":{"extent":"13","text":"32(2017), 3, Seite 536-548","volume":"32","issue":"3","pages":"536-548","year":"2017"},"pubHistory":["1.1986 -"],"title":[{"title":"Journal of bone and mineral research","subtitle":"JBMR","title_sort":"Journal of bone and mineral research"}]}]} | ||
| SRT | |a SCHEMCHRISPHARMACOLO2017 | ||